Literature DB >> 20003099

Effects of short-term food deprivation on orexin-A-induced intestinal bicarbonate secretion in comparison with related secretagogues.

G Flemström1, M W Bengtsson, K Mäkelä, K H Herzig.   

Abstract

Studies of gastrointestinal physiology in humans and intact animals are usually conducted after overnight fast. We compared the effects of orexin-A, vasoactive intestinal polypeptide (VIP), melatonin, serotonin, uroguanylin, ghrelin and prostaglandin E(2) (PGE(2)) on duodenal bicarbonate secretion in fed and overnight fasted animals. This review is a summary of our findings. Secretagogues were administered by intra-arterial infusion or luminally (PGE(2)). Enterocyte intracellular calcium ([Ca(2+)](i)) signalling was studied by fluorescence imaging. Total RNA was extracted, reverse transcripted to cDNA and expression of orexin receptors measured by quantitative real-time PCR. Orexin-A stimulates the duodenal secretion in continuously fed animals but not in food-deprived animals. Similarly, short-term fasting causes a 100-fold decrease in the amount of the muscarinic agonist bethanechol required for stimulation of secretion. In contrast, fasting does not affect secretory responses to intra-arterial VIP, melatonin, serotonin, uroguanylin and ghrelin, or that to luminal PGE(2). Orexin-A induces [Ca(2+)](i) signalling in enterocytes from fed rats but no significant [Ca(2+)](i) responses occur in enterocytes from fasted animals. In addition, overnight fasting decreases the expression of mucosal orexin receptors. Short-term food deprivation thus decreases duodenal expression of orexin receptors and abolishes the secretory response to orexin-A as well as orexin-A-induced [Ca(2+)](i) signalling. Fasting, furthermore, decreases mucosal sensitivity to bethanechol. The absence of declines in secretory responses to other secretagogues tested strongly suggests that short-term fasting does not affect the secretory capacity of the duodenal mucosa in general. Studies of intestinal secretion require particular evaluation with respect to feeding status.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20003099     DOI: 10.1111/j.1748-1716.2009.02067.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  6 in total

1.  Gastrointestinal hormones: uroguanylin-a new gut-derived weapon against obesity?

Authors:  Gema Frühbeck
Journal:  Nat Rev Endocrinol       Date:  2011-11-15       Impact factor: 43.330

Review 2.  Dietary restriction: could it be considered as speed bump on tumor progression road?

Authors:  Antonina Cangemi; Daniele Fanale; Gaetana Rinaldi; Viviana Bazan; Antonio Galvano; Alessandro Perez; Nadia Barraco; Daniela Massihnia; Marta Castiglia; Salvatore Vieni; Giuseppe Bronte; Mario Mirisola; Antonio Russo
Journal:  Tumour Biol       Date:  2016-04-04

3.  Origin of secretin receptor precedes the advent of tetrapoda: evidence on the separated origins of secretin and orexin.

Authors:  Janice K V Tam; Kwan-Wa Lau; Leo T O Lee; Jessica Y S Chu; Kwong-Man Ng; Alain Fournier; Hubert Vaudry; Billy K C Chow
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

4.  The orexin system in the enteric nervous system of the bottlenose dolphin (Tursiops truncatus).

Authors:  Claudia Gatta; Finizia Russo; Maria Grazia Russolillo; Ettore Varricchio; Marina Paolucci; Luciana Castaldo; Carla Lucini; Paolo de Girolamo; Bruno Cozzi; Lucianna Maruccio
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

5.  Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.

Authors:  Yandong Shi; Emanuela Felley-Bosco; Thomas M Marti; Katrin Orlowski; Martin Pruschy; Rolf A Stahel
Journal:  BMC Cancer       Date:  2012-12-04       Impact factor: 4.430

Review 6.  Melatonin as an Anti-Inflammatory Agent Modulating Inflammasome Activation.

Authors:  Gaia Favero; Lorenzo Franceschetti; Francesca Bonomini; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  Int J Endocrinol       Date:  2017-10-01       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.